Effect of Food on the Pharmacokinetics of the Integrase Inhibitor Dolutegravir
- 1 March 2012
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 56 (3) , 1627-1629
Abstract
Healthy subjects received dolutegravir at 50 mg in a single-dose crossover study while they were in the fasted state or with low-, moderate-, or high-fat meals. Food increased dolutegravir exposure and reduced the rate of absorption. The area under the concentration-time curve from 0 h to infinity (AUC 0–∞ ) increased by 33%, 41%, and 66% when administered with low-, moderate-, or high-fat meals, respectively, compared with fasting. This increase in dolutegravir exposure is not anticipated to impact clinical safety, and therefore dolutegravir can be taken with or without food and without regard to fat content.Keywords
This publication has 5 references indexed in Scilit:
- Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trialThe Lancet Infectious Diseases, 2012
- S/GSK1349572, a new integrase inhibitor for the treatment of HIV: promises and challengesExpert Opinion on Investigational Drugs, 2011
- Effect of Low-, Moderate-, and High-Fat Meals on Raltegravir PharmacokineticsThe Journal of Clinical Pharmacology, 2011
- In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase InhibitorAntimicrobial Agents and Chemotherapy, 2011
- Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2010